104 related articles for article (PubMed ID: 15245441)
1. Peritumoral CpG oligodeoxynucleotide treatment inhibits tumor growth and metastasis of B16F10 melanoma cells.
Kunikata N; Sano K; Honda M; Ishii K; Matsunaga J; Okuyama R; Takahashi K; Watanabe H; Tamura G; Tagami H; Terui T
J Invest Dermatol; 2004 Aug; 123(2):395-402. PubMed ID: 15245441
[TBL] [Abstract][Full Text] [Related]
2. CpG-ODN-based immunotherapy is effective in controlling the growth of metastasized tumor cells.
Kim HA; Ko HM; Ju HW; Kim KJ; Roh SG; Lee HK; Im SY
Cancer Lett; 2009 Feb; 274(1):160-4. PubMed ID: 18952369
[TBL] [Abstract][Full Text] [Related]
3. Topical CpG enhances the response of murine malignant melanoma to dacarbazine.
Najar HM; Dutz JP
J Invest Dermatol; 2008 Sep; 128(9):2204-10. PubMed ID: 18368132
[TBL] [Abstract][Full Text] [Related]
4. A self-designed CpG ODN enhanced the anti-melanoma effect of pimozide.
Jia H; Guo J; Wang P; Sun K; Chen J; Ren W; Wei T; Yang Y; Li J; Liu X; Li R; Zhong J; Wang M; Tian Z; Feng Z; Zhao T
Int Immunopharmacol; 2020 Jun; 83():106397. PubMed ID: 32220805
[TBL] [Abstract][Full Text] [Related]
5. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model.
Heckelsmiller K; Rall K; Beck S; Schlamp A; Seiderer J; Jahrsdörfer B; Krug A; Rothenfusser S; Endres S; Hartmann G
J Immunol; 2002 Oct; 169(7):3892-9. PubMed ID: 12244187
[TBL] [Abstract][Full Text] [Related]
6. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
7. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
[TBL] [Abstract][Full Text] [Related]
8. NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides.
Kawarada Y; Ganss R; Garbi N; Sacher T; Arnold B; Hämmerling GJ
J Immunol; 2001 Nov; 167(9):5247-53. PubMed ID: 11673539
[TBL] [Abstract][Full Text] [Related]
9. Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors.
Daftarian P; Song GY; Ali S; Faynsod M; Longmate J; Diamond DJ; Ellenhorn JD
Cancer Res; 2004 Aug; 64(15):5407-14. PubMed ID: 15289349
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor activity of CpG-ODN aerosol in mouse lung metastases.
Sfondrini L; Sommariva M; Tortoreto M; Meini A; Piconese S; Calvaruso M; Van Rooijen N; Bonecchi R; Zaffaroni N; Colombo MP; Tagliabue E; Balsari A
Int J Cancer; 2013 Jul; 133(2):383-93. PubMed ID: 23319306
[TBL] [Abstract][Full Text] [Related]
11. IP-10-encoding plasmid DNA therapy exhibits anti-tumor and anti-metastatic efficiency.
Keyser J; Schultz J; Ladell K; Elzaouk L; Heinzerling L; Pavlovic J; Moelling K
Exp Dermatol; 2004 Jun; 13(6):380-90. PubMed ID: 15186325
[TBL] [Abstract][Full Text] [Related]
12. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M
Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral administration of secondary lymphoid chemokine and unmethylated cytosine-phosphorothioate-guanine oligodeoxynucleotide synergistically inhibits tumor growth in vivo.
Oh SM; Oh K; Lee DS
J Korean Med Sci; 2011 Oct; 26(10):1270-6. PubMed ID: 22022177
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice.
Tormo D; Ferrer A; Bosch P; Gaffal E; Basner-Tschakarjan E; Wenzel J; Tüting T
Cancer Res; 2006 May; 66(10):5427-35. PubMed ID: 16707471
[TBL] [Abstract][Full Text] [Related]
15. Development of a novel Ag-specific immunotherapy using CpG oligodeoxynucleotides in a new, unique mouse cutaneous eosinophilic inflammation model.
Kootiratrakarn T; Fujimura T; Sano K; Okuyama R; Aiba S; Tagami H; Terui T
Eur J Immunol; 2005 Nov; 35(11):3277-86. PubMed ID: 16245360
[TBL] [Abstract][Full Text] [Related]
16. CpG immunostimulatory sequences enhance contact hypersensitivity responses in mice.
Akiba H; Satoh M; Iwatsuki K; Kaiserlian D; Nicolas JF; Kaneko F
J Invest Dermatol; 2004 Sep; 123(3):488-93. PubMed ID: 15304088
[TBL] [Abstract][Full Text] [Related]
17. Comparison of immunity in mice cured of primary/metastatic growth of EMT6 or 4THM breast cancer by chemotherapy or immunotherapy.
Gorczynski RM; Chen Z; Erin N; Khatri I; Podnos A
PLoS One; 2014; 9(11):e113597. PubMed ID: 25409195
[TBL] [Abstract][Full Text] [Related]
18. Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy.
Heckelsmiller K; Beck S; Rall K; Sipos B; Schlamp A; Tuma E; Rothenfusser S; Endres S; Hartmann G
Eur J Immunol; 2002 Nov; 32(11):3235-45. PubMed ID: 12555669
[TBL] [Abstract][Full Text] [Related]
19. B cells contribute to the antitumor activity of CpG-oligodeoxynucleotide in a mouse model of metastatic lung carcinoma.
Sorrentino R; Morello S; Forte G; Montinaro A; De Vita G; Luciano A; Palma G; Arra C; Maiolino P; Adcock IM; Pinto A
Am J Respir Crit Care Med; 2011 May; 183(10):1369-79. PubMed ID: 21278302
[TBL] [Abstract][Full Text] [Related]
20. Genetically modified murine adipose-derived mesenchymal stem cells producing interleukin-2 favor B16F10 melanoma cell proliferation.
Bahrambeigi V; Ahmadi N; Salehi R; Javanmard SH
Immunol Invest; 2015; 44(3):216-36. PubMed ID: 25565576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]